Thread regarding AstraZeneca layoffs

and yet, it'll be even worse

Here is more months for 2025:

April 2025

• Lisata Therapeutics - United States - 4 employees
  Eliminated four R&D roles as several clinical trials concluded.

• Entrada - United States - 20% workforce
  Cut staff to prioritize pipeline following FDA lift of trial hold.

• Ono Pharma - Cambridge, Massachusetts - 83 employees
  Reduced headcount at its U.S. site, effective June 30.

• Octagon Therapeutics - United States - Undisclosed number
  Shut down after deprioritizing its lead program and facing scientific uncertainty.

• Spruce Biosciences - United States - 55% workforce
  Slashed more than half its team after pivoting to a new licensed asset.

• Caribou Biosciences - United States - 32% workforce
  Cut staff and dropped a CAR-T asset to focus on two lead candidates.

• Tempest Therapeutics - United States - 80% workforce
  Reduced team to just five employees to stretch cash reserves.

• Mural Oncology - United States - 104 employees (90%)
  Laid off most of the workforce after IL-2 dr-g failure.

• Third Harmonic Bio - United States - Undisclosed number
  Abandoned lead dr-g and prepared to liquidate the business.

• Pfizer - San Diego, California - 56 employees
  Laid off staff after selling its five-building Torrey Pines campus.

• Opthea - United States - 65% workforce
  Announced deep staff cuts and operational scaling after dr-g failure.

• Organon - New Jersey - 93 employees
  Cut staff as part of an ongoing revamp since 2023.

• Vincerx Pharma - United States - Undisclosed number
  Began winding down operations after two failed merger attempts.

• Tango Therapeutics - United States - 30 employees
  Reduced spending on preclinical work and cut staff accordingly.

• Lyell Immunopharma - Los Angeles, California - 73 employees
  Closed ImmPact Bio's manufacturing facility after acquisition.

• Roche - Santa Clara, California - 108 employees
  Cut positions in its diagnostics division focused on R&D and software.

• Gilead - Foster City, California - 149 employees
  Initiated layoffs at headquarters, to take effect in May.

• Relay Therapeutics - Massachusetts - 70 employees
  Third round of layoffs, part of a broader 75% R&D budget reduction.

• Oncodesign Precision Medicine - France - 5 employees
  Made cuts after losing a partnership with Servier.

• Sail Biomedicines - United States - 12 employees
  Reduced headcount following internal structural review.

---

March 2025

• Carisma Therapeutics - United States - 40 employees (approx)
  Reduced headcount from 46 to 6 as it seeks strategic alternatives.

• Inspirna - United States - Dozens of employees
  Shut down operations, eliminating all staff.

• LifeMine Therapeutics - United States - Undisclosed number
  Slimmed down staff to focus on its lead clinical candidate.

• BioAtla - United States - Over 30% workforce
  Restructured to prioritize core programs and reduce costs.

• Nkarta - South San Francisco, California - 53 employees (34%)
  Laid off a third of workforce including half of executive leadership.

• Arbutus Biopharma - United States - Undisclosed number
  Retained only a core team to support hepatitis B trials.

• Lyndra Therapeutics - United States - 60 employees
  Wound down operations after failed financing attempts.

• ElevateBio - United States - 17% workforce
  Conducted layoffs to position for long-term success.

• Vaxart - South San Francisco, California - 10% workforce
  Cut jobs after government halted COVID-19 pill trial.

• Elevation Oncology - United States - 70% workforce
  Made deep cuts after scrapping its sole clinical asset.

• bit.bio - United Kingdom - 25% workforce
  Pivoted toward biomedical tools, resulting in layoffs.

• Cargo Therapeutics - United States - 90% workforce
  Made second major cut after abandoning its lead asset.

• Empress Therapeutics - Massachusetts - 23 employees (50%)
  Cut half of team due to delays in dr-g development progress.

• TC BioPharm - Scotland - 20 employees
  Outsourced functions and reduced workforce accordingly.

• HC Bioscience - United States - Undisclosed number
  Shut down after preclinical results failed to deliver.

• Pyxis Oncology - Boston, Massachusetts - 20% workforce
  Reduced headcount after cutting pipeline to one cancer asset.

• Novartis - East Hanover, New Jersey - 427 employees
  Reduced workforce as part of a restructuring in cardiovascular sales.

• Merck & Co. - Riverside, Pennsylvania - 163 employees
  Phased out jobs at Cherokee plant during multi-year closure plan.

• Apriori Bio - United States - 15 employees
  Reduced workforce during shift from platform to pipeline focus.

• Sutro Biopharma - United States - Nearly 50% workforce
  Cut staff and replaced CEO after deprioritizing lead asset.

• GRO Biosciences - United States - Undisclosed number
  Restructured and eliminated roles in research.

• Kiromic BioPharma - United States - 31 employees
  Furloughed nearly all staff amid a cash crisis.

• Atea Pharmaceuticals - United States - 25% workforce
  Cut jobs to save $15 million after exiting COVID dr-g development.

• ALX Oncology - United States - 30% workforce
  Focused on trials for CD47 blocker and reduced operating costs.

• Bristol Myers Squibb - Lawrenceville, NJ and Redwood City, CA - 280 employees
  Rolled out new waves of layoffs in two states.

• Atara Biotherapeutics - United States - 50% workforce
  Halved headcount after FDA halted trials of two key assets.

---

February 2025

• CRISPR Therapeutics - United States - Undisclosed number
  Quietly laid off employees across research and manufacturing.

• Eisai - United States - 121 employees
  Restructured U.S. operations and eliminated commercial roles.

• Ryvu Therapeutics - Poland - 30% workforce
  Focused remaining resources on phase 3 blood cancer dr-g.

• Lava Therapeutics - United States - 30% workforce
  Cut jobs after terminating lead blood cancer program.

• Repare Therapeutics - United States - 75% workforce
  Conducted major layoffs following earlier announcements.

• Spotlight Therapeutics - San Francisco, California - All employees
  Shut down company operations entirely.

• Kojin Therapeutics - Boston, Massachusetts - Undisclosed number
  Began winding down and prepared to close over coming months.

• Moderna - United States - 50 employees (10% of IT team)
  Cut digital department roles after CIO's departure.

• Encoded Therapeutics - United States - 29% workforce
  Focused resources on Dravet syndrome and eliminated early R&D roles.

• Inventiva - France - 50% workforce
  Reduced staff to concentrate on MASH dr-g development.

• Third Harmonic Bio - United States - 50% workforce
  Scaled down in preparation for next clinical stage.

• Q32 Bio - United States - Undisclosed number
  Cut workforce and paused programs to conserve cash.

• X4 Pharmaceuticals - United States and Austria - 43 employees (30%)
  Closed Vienna site and paused all pre-clinical efforts.

• Viracta Therapeutics - San Diego, California - All employees
  Closed the company and laid off full staff.

• Frontier Medicines - United States - Undisclosed number
  Streamlined operations for efficiency and impact.

• Kyowa Kirin - Princeton, New Jersey - 52 employees
  Conducted layoffs at its North American headquarters.

• Bristol Myers Squibb - New Jersey - 67 employees
  Continued layoffs under ongoing cost-cutting plan.

• Turnstone Biologics - San Diego, California - Undisclosed number
  Reduced workforce while seeking strategic alternatives.

• Omega Therapeutics - United States - Up to 17 employees
  Faced possible bankruptcy and workforce reduction.

---

January 2025

• Cargo Therapeutics - United States - 50% workforce
  Cut jobs after discontinuing lead candidate with weak results.

• Ironwood Pharmaceuticals - United States - 50% workforce
  Halved staff to focus on investigational bowel syndrome treatment.

• I-Mab - United States - 27% workforce
  Restructured pipeline and reduced staff accordingly.

• Zentalis Pharmaceuticals - United States - 40% workforce
  Reduced headcount to extend cash through 2026.

• Allakos - United States - 75% workforce
  Made deep cuts after lead dr-g failed in phase 1.

• Biogen - United States - Undisclosed number
  Reallocated resources by reducing research team.

• Notch Therapeutics - Canada - Undisclosed number
  Made layoffs due to fundraising and partnership struggles.

• Apellis Pharmaceuticals - Global (non-US) - 40 employees
  Prioritized U.S. commercialization and cut international roles.

• Barinthus Bio - US and UK - 65% workforce
  Halted hepatitis B program and reduced headcount substantially.

• Passage Bio - Philadelphia, Pennsylvania - 55% workforce
  Shifted from in-house to outsourced testing model.

• Y-mAbs Therapeutics - Denmark and US - Up to 13% workforce
  Relocated and consolidated roles as part of a reorganization.

• Repare Therapeutics - United States - Undisclosed number
  Followed up previous layoff with additional undisclosed cuts.

• Intellia Therapeutics - United States - 27% workforce
  Reduced headcount and paused pipeline to aim for 2027 launch.

• Shoreline Biosciences - United States - Undisclosed number
  Cut employees from a discontinued collaboration with Gilead.

• IGM Biosciences - United States - 73% workforce
  Refocused on autoimmune diseases and closed most operations.

• Velia Therapeutics - United States - Undisclosed number
  Wound down company operations entirely.

• Scribe Therapeutics - United States - 20% workforce
  Cut roles while advancing clinical development plans.

• Galapagos - United States and Europe - 40% workforce (approx. 300 employees)
  Restructured by splitting company into two divisions.

• Cassava Sciences - United States - 33% workforce
  Reduced staff after Alzheimer’s trial failure.

• CytomX Therapeutics - California - 40% workforce
  Cut staff and reassessed strategic partnerships.

---